CBD (cannabidiol) is a non-intoxicating cannabinoid with FDA-approved use (Epidiolex) for severe epilepsy and moderate evidence for anxiety reduction. Our research shows the clinical evidence is MUCH thinner than the marketing suggests: the strongest evidence is for Dravet/Lennox-Gastaut syndrome epilepsy (FDA-approved), followed by a single acute anxiety study (300mg reduced social anxiety). For chronic pain, sleep, and general "wellness" — the claims massively outpace the evidence. The BIGGEST concern: CBD is a potent CYP3A4 and CYP2C19 inhibitor, meaning it interacts with ~60% of prescription drugs. And the supplement market is a disaster — 28% of products contained less CBD than labeled, 21% contained THC above legal limits.
CBD's pharmacology is complex and NOT primarily mediated through cannabinoid receptors: (1) 5-HT1A partial agonist — the serotonin receptor responsible for CBD's anxiolytic effects (same receptor targeted by buspirone); (2) TRPV1 agonist — vanilloid receptor activation, desensitization → pain modulation; (3) GPR55 antagonist — orphan cannabinoid receptor involved in cancer cell proliferation; (4) Allosteric modulator of CB1 — does NOT directly activate CB1 (that's THC) but modulates its signaling; (5) Adenosine reuptake inhibition — increases extracellular adenosine (anti-inflammatory, neuroprotective); (6) PPARγ agonist — nuclear receptor activation for anti-inflammatory effects; (7) CYP3A4 and CYP2C19 inhibition — MAJOR drug interaction mechanism.
Based on independent third-party laboratory analysis
Category pass rate: ~80% for CBD content. THC contamination is the key risk — 1 in 7 "full spectrum" users fail drug tests.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.